Overview

Treatment With SU11248 in Patients With Neuroendocrine Tumors

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib